Aripiprazolecamberlogo (Aripiprazolecamberlogo)
Aripiprazole Solution
Product Images NDC 31722-684
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 31722-684). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Aripiprazolecartonlabel (Aripiprazolecartonlabel)
The packaging label for Aripiprazole Oral Solution 1 mg/mL by Camber Pharmaceuticals, Inc. It is a 150 mL bottle prescription oral solution. The label includes dosing and storage instructions, pharmacist dispensing guidance, a U.S. contact number, and manufacturing details including the license number and Indian manufacturer information. The label design features red and black text on a white background with pink accents.*
Aripiprazolecontainerlabel (Aripiprazolecontainerlabel)
The label for Aripiprazole Oral Solution 1 mg/mL by Camber Pharmaceuticals, Inc. It indicates the product is a 150 mL oral solution prescription drug (NDC 31722-684-15) with tamper-evident seal instructions, storage conditions, and usage information. The label includes a barcode, pharmacist directions, and manufacturer details.*
Aripiprazolefigure1 (Aripiprazolefigure1)
A scatter plot chart showing the effect of various other drugs on Aripiprazole pharmacokinetics (PK). It displays Aripiprazole fold change and 90% confidence intervals for AUC and Cmax values when co-administered with CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blockers famotidine, and other drugs valproate, lithium, and lorazepam. The x-axis shows change relative to reference without interacting drug, ranging from 0.5 to 3.0.*
Aripiprazolefigure2 (Aripiprazolefigure2)
A horizontal bar chart titled 'Effect of Other Drugs on Aripiprazole' showing the fold change and 90% confidence interval of dehydro-aripiprazole pharmacokinetic parameters (AUC and Cmax) relative to reference without interacting drug. The chart compares the effects of CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other drugs such as valproate, lithium, and lorazepam on aripiprazole exposure.*
Aripiprazolefigure3 (Aripiprazolefigure3)
A forest plot chart titled 'Effect of Aripiprazole on Other Drugs' illustrating fold change and 95% confidence intervals for various drugs affected by Aripiprazole. The chart compares pharmacokinetic parameters such as AUC and Cmax versus controls, including drugs like diazepam, warfarin, omeprazole, lamotrigine, valproate, lithium, and escitalopram, showing changes relative to control (no Aripiprazole).*
Aripiprazolefigure4 (Aripiprazolefigure4)
A chart titled "Aripiprazole Fold Change and 90% CI" illustrating pharmacokinetic data for Aripiprazole oral solution. It shows fold change on the x-axis relative to reference, for special populations based on CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment. The graph plots AUC and Cmax values with confidence intervals for each category.*
Aripiprazolefigure5 (Aripiprazolefigure5)
A forest plot depicting the fold change and 90% confidence interval for dehydro-aripiprazole pharmacokinetics (PK) parameters (AUC and Cmax) relative to reference values. The variables analyzed include CYP2D6 metabolism status (poor vs. extensive), gender, age groups (18-64 vs. >65 years), and degrees of hepatic and renal impairment, showing the impact of these factors on drug exposure.*
Aripiprazolefigure6 (Aripiprazolefigure6)
A line graph showing the proportion of subjects with response over 182 days from randomization, comparing Aripiprazole and placebo groups. The x-axis denotes days from randomization and includes the number of subjects at risk at various time points. The y-axis indicates the proportion with response, ranging from 0.0 to 1.0, with Aripiprazole consistently showing a higher response proportion than placebo throughout the study period.*
Aripiprazolefigure7 (Aripiprazolefigure7)
A line graph comparing the proportion of subjects with relapse over 182 days from randomization between Aripiprazole and placebo groups. The x-axis shows days from 0 to 182, and the y-axis shows the proportion with relapse from 0 to 1. The graph includes a table below indicating the number of subjects at risk at various time points for both groups.*
Aripiprazolefigure8 (Aripiprazolefigure8)
A line graph comparing the proportion with relapse over time between Aripiprazole oral solution 1 mg/mL and placebo groups. The x-axis shows days from randomization up to 182 days, while the y-axis represents the proportion with relapse. The graph includes subject numbers at risk at various time points for both groups.*
Aripiprazolefigure9 (Aripiprazolefigure9)
A line graph showing the change in YGTSS total tic score from baseline over weeks of treatment. The graph compares three groups: Aripiprazole low dose, Aripiprazole high dose, and placebo, depicting their least-squares mean change scores over time.*
Aripiprazolestructure (Aripiprazolestructure)
Chemical structure of aripiprazole, an antipsychotic agent. The diagram shows the molecular structure including rings, bonds, and chlorine (Cl) atoms consistent with aripiprazole's chemical composition.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
